Compare ICCM & ELUT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ICCM | ELUT |
|---|---|---|
| Founded | 2006 | 2015 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | | Medical Specialities |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 41.4M | 46.5M |
| IPO Year | 2013 | 2020 |
| Metric | ICCM | ELUT |
|---|---|---|
| Price | $0.60 | $1.09 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $2.50 | ★ $6.00 |
| AVG Volume (30 Days) | ★ 251.7K | 171.3K |
| Earning Date | 03-17-2026 | 03-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 146.77 |
| EPS | N/A | ★ 0.87 |
| Revenue | N/A | ★ $12,293,000.00 |
| Revenue This Year | $53.39 | N/A |
| Revenue Next Year | $487.34 | $10.83 |
| P/E Ratio | ★ N/A | $1.22 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.54 | $0.50 |
| 52 Week High | $1.40 | $2.99 |
| Indicator | ICCM | ELUT |
|---|---|---|
| Relative Strength Index (RSI) | 48.34 | 51.40 |
| Support Level | $0.58 | $0.89 |
| Resistance Level | $0.62 | $1.15 |
| Average True Range (ATR) | 0.05 | 0.13 |
| MACD | -0.00 | -0.02 |
| Stochastic Oscillator | 26.34 | 26.25 |
Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.
Elutia Inc Formerly Aziyo Biologics Inc is a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, concentrating on patients receiving implantable medical devices. The company's segments include Device Protection, Women's Health and Cardiovascular. It generates maximum revenue from the Women's Health segment. The products of the company are targeted to address unmet clinical needs with the goal of promoting healthy tissue formation and avoiding complications associated with medical device implants, such as scar-tissue formation, capsular contraction, erosion, migration, non-union of implants and implant rejection.